An open-label study to assess the long-term effects of rasagiline on cumulative disability in Parkinson\'s disease: design and baseline data from the ADAGIO follow-up study by Prof. Fabrizio Stocchi given during the 15th Congress of the European Federation of Neurological Societies powered by - MULTIWEBCAST

15th Congress of the European Federation of Neurological Societies

LISTING OF ePOSTERS

ePosters

BROWSE:

An open-label study to assess the long-term effects of rasagiline on cumulative disability in Parkinson\'s disease: design and baseline data from the ADAGIO follow-up study

Prof. Fabrizio Stocchi

Italy

Disclosure : This study is supported by Teva Pharmaceutical Industries Ltd (Israel), Teva Neuroscience Inc (USA) and H.Lundbeck A/S (Denmark).
Prof. Stocchi reports consulting fees from Teva, Lundbeck, GlaxoSmithKline, Boehringer Ingleheim, Newron, Merck Serono, Novartis, Impax, Schering Plaugh, Chiesi pharma and UCB.

[More] [Less]

Topic: Poster Session 1: Movement disorders 1

VIEW ePOSTER

16 slide(s) – English – 2011-09-10

Rate & Comment

A A A


Rate:
Please let us know how useful this content was for you and feel free to write your comments below.

Disclaimer ^{AMENDED ON January 29, 2009} | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

Search’n Build™